Walter V. Klemp, CEO, President, and Director of Moleculin Biotech, Inc. (NASDAQ:MBRX), filed a Form 4 on November 6, 2026, disclosing transactions dated November 4, 2026, related to the vesting of restricted stock units.
Key Highlights
- RSU conversion: 57 restricted stock units were converted into 57 shares of common stock on November 4, 2026, on a one-for-one basis.
- Tax withholding: 14 shares were withheld at $8.46 per share for payment of taxes upon vesting.
- Resulting ownership: Klemp directly beneficially owned 36,203 shares of common stock following the reported transactions.
- Remaining RSUs: Klemp held 127,415 restricted stock units following the transactions.
- Original grant: According to the filing, the 230 restricted stock units underlying the vesting were originally granted on November 4, 2024, vesting in four equal annual installments beginning on the first anniversary of the grant date.
- Filer role: Klemp serves as CEO and President, and is also identified as a Director of the issuer.
Moleculin Biotech CEO Klemp: November 2026 RSU Vesting Details
According to the Form 4 filed with the SEC on November 6, 2026, Walter V. Klemp, who serves as CEO, President, and Director of Moleculin Biotech, Inc. (NASDAQ:MBRX), reported two transactions in common stock on November 4, 2026. The first transaction, coded "M," reflects the conversion of 57 restricted stock units into 57 shares of common stock, acquired at a price of $0, consistent with the filing's explanation that restricted stock units convert into common stock on a one-for-one basis.
The second transaction, coded "F," reflects 14 shares disposed of at a price of $8.46 per share. The filing states these shares were "withheld for payment of taxes upon vesting of restricted stock unit awards." After both transactions, Klemp's direct beneficial ownership of common stock stood at 36,203 shares, the filing disclosed.
In Table II, the filing reports that Klemp's remaining directly held restricted stock units totaled 127,415 following the November 4, 2026 vesting. The filing notes that the original grant of 230 restricted stock units was made on November 4, 2024, with vesting scheduled in four equal annual installments beginning on the first anniversary of the grant date. The Form 4 was signed by Jonathan P. Foster by Power of Attorney on November 6, 2026.
What Was Disclosed
Moleculin Biotech's CEO and President Walter V. Klemp reported the vesting of 57 restricted stock units on November 4, 2026, with 14 shares withheld for taxes at $8.46 each, leaving him with 36,203 shares of common stock and 127,415 remaining restricted stock units.





Please wait processing your request...